Lipum’s toxicology- and safety studies on the candidate drug SOL-116 progress according to plan
Press release: Umeå, September 3, 2021. The dose-finding toxicology- and safety studies on Lipum’s candidate drug (SOL-116) have been completed according to plan and the final Clinical Trial Application (CTA)-enabling toxicology study has now started.The non-clinical program for toxicology- and safety studies of Lipum’s candidate drug (SOL-116) is carried out in collaboration with the contract research organisation (CRO) Charles River Laboratories. Previous dose finding studies, which included various dose levels, were conducted in two different species with a treatment period of four weeks.